Summary: The Centers for Medicare & Medicaid Services modified its cellular therapy coverage policy, effective May 15, 2026. Here's what billing teams need to know before that date.
CMS cellular therapy coverage policy changes carry significant financial exposure. Cellular therapies—including CAR-T treatments and stem cell infusions—generate some of the highest-cost claims in oncology and hematology billing. When the Centers for Medicare & Medicaid Services modifies coverage criteria for these services, your denial rate and reimbursement outcomes follow. This policy does not carry a traditional policy code, but it governs coverage determinations that affect a broad range of specialties billing cellular therapy services to Medicare.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | CMS (Centers for Medicare & Medicaid Services) |
| Policy | Cellular Therapy |
| Policy Code | N/A |
| Change Type | Modified |
| Effective Date | May 15, 2026 |
| Impact Level | High |
| Specialties Affected | Oncology, Hematology, Bone Marrow Transplant Programs, Cell Therapy Centers |
| Key Action | Audit all pending and active cellular therapy claims against updated coverage criteria before May 15, 2026 |
CMS Cellular Therapy Coverage Criteria and Medical Necessity Requirements 2026
CMS does not cover cellular therapy broadly. Coverage has historically been narrow, conditional, and tied to specific clinical contexts where medical necessity can be clearly documented.
The underlying framework for CMS cellular therapy coverage policy has always required that services meet the definition of "reasonable and necessary" under Section 1862(a)(1)(A) of the Social Security Act. That means your documentation must establish that the treatment is appropriate for the patient's specific diagnosis, consistent with accepted standards of medical practice, and not experimental in the context being billed.
The specific coverage criteria in the modified policy are not publicly detailed in the version available at the time of this writing. However, based on CMS's established framework for cellular therapy, medical necessity documentation typically must address the patient's diagnosis, prior treatment history, and clinical rationale for the cellular therapy approach selected.
Prior authorization requirements vary by Medicare Administrative Contractor region. Some MACs have issued local coverage determinations that add criteria on top of the national policy. Check with your MAC before May 15, 2026 to confirm whether a local coverage determination applies to your claims.
The real issue with CMS cellular therapy billing is that the line between covered and non-covered is rarely obvious at the point of care. A CAR-T infusion for a Medicare patient with relapsed diffuse large B-cell lymphoma looks very different to a claims reviewer than the same procedure billed for an off-label indication. Documentation has to make that distinction airtight before the claim goes out.
CMS Cellular Therapy Exclusions and Non-Covered Indications
CMS has historically excluded several cellular therapy applications from coverage on the grounds that they are experimental or investigational. This is the area where most claim denials originate.
Autologous cellular therapy for conditions outside established clinical evidence—including certain solid tumors and autoimmune conditions without a robust evidence base—has not met CMS's medical necessity standard in prior policy iterations. Services provided solely within a research protocol, without separate clinical justification, also face coverage barriers.
The modified policy's specific exclusion language is not available in the source document at time of publication. But the pattern here matches what CMS did with genetic testing coverage policy revisions in recent years: the agency tightens the covered indications list, which by implication narrows what passes medical necessity review. If you bill cellular therapy for indications that weren't explicitly covered before this modification, assume those indications are under higher scrutiny now—not less.
Talk to your compliance officer before May 15, 2026 if your program bills cellular therapy for any indication that sits at the edge of current coverage criteria.
Coverage Indications at a Glance
Because the full policy detail is not available in the source document, this table reflects CMS's established coverage framework for cellular therapy. Confirm specific indications against the full policy text at the effective date.
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| CAR-T cell therapy for approved hematologic malignancies | Covered (when criteria met) | Confirm with MAC | Medical necessity documentation required; prior auth may apply by MAC |
| Allogeneic stem cell transplantation for covered diagnoses | Covered (when criteria met) | Confirm with MAC | Diagnosis-specific criteria apply |
| Cellular therapy within clinical trial only (no independent clinical justification) | Not Covered | N/A | Research-only context does not satisfy medical necessity standard |
| Cellular therapy for investigational or off-label indications | Not Covered / Experimental | N/A | High claim denial risk; documentation burden falls on provider |
| Autologous therapy for solid tumors without established evidence | Experimental | N/A | CMS has historically excluded these; verify under updated policy |
This table reflects historical CMS cellular therapy coverage framework. Confirm all indications against the May 15, 2026 policy text.
CMS Cellular Therapy Billing Guidelines and Action Items 2026
The effective date is May 15, 2026. That gives your billing team a defined window to act. Here's what to do now.
| # | Action Item |
|---|---|
| 1 | Pull every open cellular therapy claim and compare it against the updated policy. If you have claims in process that span the effective date, you need to know which version of the coverage policy applies. CMS generally applies the policy version in effect on the date of service, not the date of billing. |
| 2 | Verify your MAC's local coverage determination for cellular therapy. The national policy sets the floor. Your Medicare Administrative Contractor may have an LCD that adds criteria, restricts covered diagnoses, or requires prior authorization. Ignorance of the LCD is not a defense at appeal. |
| 3 | Audit your medical necessity documentation templates. Every cellular therapy claim needs documentation that maps the patient's diagnosis, prior treatment history, and clinical rationale directly to the coverage criteria. Generic clinical notes will not survive a post-payment audit. |
| 4 | Update your prior authorization workflows before May 15, 2026. If the modified policy changes coverage criteria, it may also change which services require prior auth under your MAC's rules. Confirm this with your MAC's provider relations team directly. |
| 5 | Flag any cellular therapy reimbursement that has been processed under the old policy criteria. If you've been billing under criteria that the modified policy narrows, you may have overpayments in your claim history. Get ahead of that with your compliance officer rather than waiting for a recovery audit. |
| 6 | Brief your medical directors and treating physicians now. Cellular therapy billing failures almost always start with documentation gaps at the clinical level. Your physicians need to know what the updated coverage criteria require before they're writing the notes that support your claims. |
| 7 | If you're unsure how the modified criteria apply to your patient population, contact your compliance officer or a qualified billing consultant before May 15, 2026. These are high-value claims. A single wrongly denied or improperly billed cellular therapy claim can represent tens of thousands of dollars in exposure. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Cellular Therapy Under CMS Cellular Therapy Policy
The CMS cellular therapy policy as provided does not list specific CPT, HCPCS Level II, or ICD-10-CM codes in the source document available at time of publication.
This is worth flagging directly: the absence of a code list in a policy modification is itself a signal. It means the coverage policy operates at the level of clinical criteria and medical necessity standards, not at the level of individual procedure codes. Your billing team cannot rely on a code list alone to determine coverage. The criteria in the policy text govern.
What Your Billing Team Should Do in the Absence of a Published Code List
Pull the full policy text directly from CMS when it publishes on or before May 15, 2026. CMS cellular therapy coverage has historically intersected with the following code categories—but confirm these against the actual published policy before using them in your charge capture:
- CAR-T and cellular immunotherapy services — typically reported under HCPCS codes specific to the product (e.g., tisagenlecleucel, axicabtagene ciloleucel, idecabtagene vicleucel). These are product-specific J-codes and require exact code matching to the administered product.
- Stem cell transplant procedures — reported under CPT codes in the 38240–38243 range historically, though CMS coverage criteria are diagnosis-specific.
- Administration and infusion services — reported under relevant infusion CPT codes depending on the service setting.
Do not update your charge capture based on this list alone. Confirm codes against the published policy and your MAC's LCD before May 15, 2026.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.